Analytical Data
-
Gene name
AHSP
- Application
-
Alternative Names
Erythroid differentiation-related factor Erythroid-associated factor
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NZD4
-
Expression Region
1-102aa
-
Molecular Weight
38.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ASXL1 (Additional Sex Combs Like 1) is a gene that plays a crucial role in epigenetic regulation and chromatin remodeling. Mutations in ASXL1 have been linked to various hematological malignancies, particularly myeloid malignancies such as Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS). These mutations often result in a loss of function, leading to abnormal gene expression and disrupted cellular differentiation processes. The ASXL1 protein is known to function as a component of the Polycomb Repressive Complex 2 (PRC2), influencing gene silencing and maintaining cell identity. Research has shown that ASXL1 mutations are associated with poor prognosis and may contribute to the pathogenesis of malignancies by promoting hematopoietic stem cell self-renewal and impairing differentiation. Recent studies have also examined the interaction of ASXL1 with other oncogenic pathways and its role in the response to therapy. Understanding the molecular mechanisms by which ASXL1 mutations drive tumorigenesis is critical for developing targeted therapies and improving patient outcomes in cancers where ASXL1 alterations are prevalent. Furthermore, the exploration of ASXL1 as a potential biomarker for diagnosis and prognostication in hematological cancers remains an area of active investigation, underscoring its significance in both clinical and research settings.
